MY

Mohammad Yaseen

Active Director Director DIN 10386203
DIN 10386203 First appointment Nov 2023
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2023
Shareholding value •••• Premium profile

About Mohammad Yaseen

Data last updated:

Mohammad Yaseen is a Director at Frankcure Pharma Private Limited (since 2023). Frankcure Pharma Private Limited reported revenue of ₹24,327 (FY 2024).

DIN 10386203
Primary Designation Director
First Appointment 08 Nov 2023
Oldest Company Age 2 yrs
Largest company Frankcure Pharma Private Limited · ₹24,327 (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Frankcure Pharma Private Limited U47721UP2023PTC192240
Director08 Nov 20232023₹24,327 (FY 2024)Active

Board colleagues of Mohammad Yaseen

NameDINCompanyDesignation
Mohammad Faiz Raza Ansari10386204Frankcure Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Frankcure Pharma Private Limited
Premium access

Shareholding and investment profile for Mohammad Yaseen

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mohammad Yaseen

Mohammad Yaseen currently holds 1 directorship: Frankcure Pharma Private Limited (Director, since 08 Nov 2023, revenue ₹24,327 (FY 2024)).

Mohammad Yaseen was first appointed on 08 Nov 2023 as Director at Frankcure Pharma Private Limited.

The current boards of Mohammad Yaseen's companies include Mohammad Faiz Raza Ansari (Frankcure Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available